EDGE MEDICAL
精锋医疗

Shenzhen Edge Medical Co., Ltd.
深圳市精鋒醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2675)

VOLUNTARY ANNOUNCEMENT
INVESTMENT IN PRIMALVERSE

This announcement is made by Shenzhen Edge Medical Co., Ltd. (the "**Company**") on a voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company has completed the investment (the "**Investment**") in PrimalVerse (Beijing) Technology Co., Ltd.* (元昊動力(北京)科技有限公司) ("**PrimalVerse**"), a third party who is independent of the Company and its connected person(s) (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). The Investment will further enhance the Company's capabilities in exploring the intelligent surgery field of "AI + surgical robots" and establish a strategic foundation for the Company's embodied AI surgical robot business.

Information about PrimalVerse

PrimalVerse is an artificial intelligence enterprise specializing in the research and development of foundation models for the fifth-generation multi-modal 4D world models. Founded by a world model research team with educational background from Tsinghua University, PrimalVerse focuses on native 4D world representations, and has constructed a unified model architecture covering dynamic world reconstruction, generation, simulation and intelligent agent training. It has taken the lead in advancing applications across use cases including embodied intelligence, autonomous surgery, gaming, film and television, as well as autonomous driving, with the corporate mission to build a general-purpose world model infrastructure for the physical AI era.

Reasons for and Benefits of the Investment

The Company is principally engaged in designing, developing and manufacturing of surgical robots and instruments for minimally invasive surgeries (MIS), which delivers innovative solutions for surgical procedures.

The Investment will enable the Company to establish a strategic presence in the application field of embodied intelligence for "AI + surgical robotics", lay the foundation for cooperation with relevant technical teams, and explore the feasibility of expanding from standalone surgical robotic devices to an embodied intelligence surgical robotic platform.

The Board is of the view that the Investment is in the interests of the Company and its shareholders as a whole.

As all applicable percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules are below 5%, the Investment does not constitute a notifiable transaction under the Listing Rules.

Shareholders and potential investors of the Company should exercise caution when dealing in the shares and other securities of the Company.

* *The English translation is for identification purposes only.*

By order of the Board
Shenzhen Edge Medical Co., Ltd.
(深圳市精鋒醫療科技股份有限公司)
Dr. Wang Jianchen
Chairman of the Board and Executive Director

PRC, July 24, 2026

As at the date of this announcement, the Board comprises Dr. Wang Jianchen, Dr. Gao Yuanqian, and Ms. Wu Mengyuan as executive directors; Mr. Sheng Li, Mr. Chen Gang, and Mr. Qiu Xiang as non-executive directors; and Mr. Yang Fan, Mr. Zhang Guoguang and Mr. Lau Ying Kit as independent non-executive directors.